Citius Oncology, Inc. (CTOR) Stock Forecast & Price Target
Citius Oncology, Inc. · NASDAQ
$0.93+0.07 (+8.05%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Citius Oncology, Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $6.00 to $6.00, so the covering firms are broadly aligned. The average target of $6.00 sits 546% above the current $0.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.00 next quarter toward $0.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Citius Oncology, Inc.
As of Aug, 1 of 1 firms rate CTOR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTOR EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 1 analysts · -100% YoY
Next period, 1 analysts expect Citius Oncology, Inc. to earn $0.00 a share (range $0.00 – $0.00), versus $-0.06 a year earlier. Full-year consensus is $-0.56, growing to $0.10 the year after.
REVENUE · NEXT QUARTER
$14.3M
Range $14.3M – $14.3M · 1 analysts · +262% YoY
Revenue is expected to reach $14.3M (range $14.3M – $14.3M), +261.9% year-over-year. Full-year consensus is $13.9M, rising to $95.2M next year.
Top analysts covering Citius Oncology, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTOR.
#1
Michael Okunewitch
Maxim Group
Buy
$6.00+545.7% to target
Coverage
—
+ Follow
CTOR stock forecast FAQ
What is CTOR's average 12-month price target?+
The 1 analysts with a live target average $6.00 for Citius Oncology, Inc. over the next 12 months, ranging from a $6.00 high to a $6.00 low.
Is CTOR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CTOR?+
1 analysts have an active rating on Citius Oncology, Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTOR?+
Among analysts who currently cover CTOR, Michael Okunewitch of Maxim Group has the strongest overall Quantellect track record. Their current call is Buy with a $6.00 target.
What is Citius Oncology, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 1 analysts. Full-year EPS is projected at $-0.56, rising to $0.10 the following year.
How much revenue is Citius Oncology, Inc. expected to report next quarter?+
Consensus revenue is $14.3M (range $14.3M – $14.3M). Full-year revenue is projected at $13.9M, growing to $95.2M next year.
Have analysts been upgrading or downgrading CTOR lately?+
As of Aug, 1 of 1 firms rate CTOR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTOR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
